Early Access — free while we kick the tires
EdgarHawk

Remmel H. Lawrence

Director

Director
1 filing analyzed · 1 company · Latest 2025-03-28

Companies

Company Buys Sells Direction
ATOSSA THERAPEUTICS, INC. ATOS 1 0 Net buying

Activity

March 2025
high
Buy
10,000 shares
$7,000
Significance 6/10

Director Remmel H. Lawrence buys 10,000 shares of ATOS at $0.70, raising holdings 3891.1%; company posted $-7.2M net loss and -99.7% revenue decline

Remmel H. Lawrence, a Director, purchased 10,000 shares at $0.70 on 2025-03-26, increasing his stake from 257 shares to 10,257 shares—a 3891.1% increase in holdings. This substantial accumulation occurs against a backdrop of severe operational distress: the company reported zero revenue in the latest quarter, a net income loss of $-7.2M on a full-year basis, and an annual revenue decline of -99.7%, indicating the business has effectively collapsed operationally. The stock currently trades at $10.44, a 66.9% decline from its 52-week high of $31.50, and has fallen 9.5% over 30 days and 29.1% over 90 days. The purchase price of $0.70 represents a dramatic discount to the current market price, suggesting the director acquired these shares before a recent recovery or revaluation event. This pattern—a substantial insider purchase at a depressed historical entry point amid fundamental deterioration—warrants examination to determine whether the purchase reflects a disciplined conviction in a turnaround thesis or if other factors (such as scheduled or contingent equity agreements) are driving the transaction.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access